Volume : 11, Issue : 01, January – 2024
Title:
A STUDY ON DRUG-DRUG INTERACTION BETWEEN PERINDOPRIL AND GLIMEPIRIDE IN RATS
Authors :
Mohammed Hasnuddin, Ather Javed, Dr.Abdul Sayeed
Abstract :
Background and Objectives:The risk of hypoglycemia was reported with ACE inhibitors in patients who are taking insulin or other hypoglycemic agents. But there are no reports available about the drug-drug interaction between perindopril and glimepiride. Hence, the present study was planned to study the influence of single and repeated dose treatment of perindopril on the hypoglycemic and antidiabetic effect of glimepiride in normal and streptozotocin induced diabetic albino rats.
Methods: 14 groups of normal albino rats (Group I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII and XIV) (n=6) were selected. At “0” hour blood samples were collected from tail vein then groups I, II, III, IV, V and VI were administered with vehicle, glimepiride 10 mg/kg, perindopril 2.5 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg p.o respectively. After drug treatment at 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 12.0, 18.0, 24.0 and 30.0 h blood samples were collected and analyzed for serum glucose by GOD/POD method. Similarly blood samples were collected from groups VII, VIII, IX and X and were administered with single doses of perindopril 2.5 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg, p.o respectively followed by single dose of glimepiride 10 mg/kg, p.o 30 min later. Groups XI, XII, XIII and XIV were administered with different doses of perindopril 2.5 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg p.o for 7 days and on 8th day 30 min after administration of last dose of perindopril a single dose of glimepiride 10 mg/kg was administered orally. After drug treatment at 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 12.0, 18.0, 24.0 and 30.0 h blood samples were collected and analyzed for serum glucose levels as mentioned above. Similarly the experiments were conducted in diabetic rats following the above procedure and serum glucose levels were analyzed as mentioned earlier.
Results: Perindopril significantly altered the peak effect and enhanced the duration of hypoglycemic activity but not altered onset of action of glimepiride in both normal and diabetic rats.
Interpretation and Conclusion: The study suggests that, the dose and frequency of glimepiride must be readjusted when it is to be administered concomitantly with antihypertensive drug perindopril in hypertension and diabetic conditions to avoid severe hypoglycemia due to perindopril.
Key words: Glimepiride, Perindopril, hypoglycemic, antidiabetic, drug- drug interaction.
Cite This Article:
Please cite this article in press Mohammed Hasnuddin et al., A Study On Drug-Drug Interaction Between Perindopril And Glimepiride In Rats, Indo Am. J. P. Sci, 2024; 11 (01).
Number of Downloads : 10
References:
1. Herfindal EJ, Gourley DR. Text book of therapeutics. Drug and disease management. 7th ed., Lippincott Williams and Wilkins; 2000.
2. Rang H, Dale MM, Ritter JM, Moore PK. Pharmacology; Chapter 51; 5th ed., London:Churchill Livingstone; 2003.
3. Gupta B, Jaju BP. Glucose homeostasis and dugs acting on CNS: Interactions with antidiabetic agents. Ind J Pharmacol 1994; 26: 169 – 178.
4. Shah MM, Upasani CD, Bharatrajan R, Balaraman R, Rathod SP. Effect of dietary calcium, lisinopril and insulin on diabetic hypertensive animals. Ind J Pharmacol 1999; 31: 195-99
5. Stockley IH. Drug interactions. 5th ed. London: Pharmaceutical Press; 1999.
6. Hanstein PD. Drug interactions. 4th ed., Lea and Febigher/Vargheese; 1979.
7. Tortora GJ, Sandra Reynolds Grabowski. Principles of anatomy and physiology. 10th ed., New York: John Wiley and Sons; 2003.
8. Joel Hardman G, Lee Limbird E. Goodman and Gillman’s. The pharmacological basis of therapeutics.11th ed., McGraw-Hill medical publishing division; 2006.
9. Yeolkar ME, Borade PS. Classification of Diabetes and Its implications. The J General Medicine Jan-Mar 2002; 14(1):7-8.
10. http://rezidentiat.3x.ro/eng/dzeng.htm.Access date 14/10/2009.
11. Aumir M. Microalbuminuria as a predictor of diabetic retinopathy in non- Insulin Dependent Diabetes Mellitus (Unpublished PG Thesis, MD,General Medicine) Rajiv Gandhi University of Health Scientific, Karnataka, 2002.
12. Drucqer MH and McNally PG. Diabetes management step by step, 1st ed., Black well Science, Publication; 1998.
13. Verspohl EJ. Recommended testing in diabetes research. Planta Medica 2002, 68:581-90.
14. http://diabetes.niddk.nih.gov/dm/pubs/diagnosis.Access date 16/10/2009.
15. http://rezidentiat.3x.ro/eng/dzeng.htm.Access date 20/10/2009.
16. Chattopadhyay S. Animal models in experimental diabetes mellitus. Ind J Exp Biol 1997; 1141-45.
17. Vogel HG. Drug discovery and evaluation of Pharmacological assays, 2nd ed., Springer-Verlag Berlin Heidelberg publications; 1997.
18. Kodama T, Iwase M, Nunoi Y, Yoshinari M, Fujishima M. A new diabetes model induced by neonatal Alloxan treatment in rats. Diabet Res Clin Pract Jun 1993; 20(3):183-9.
19. Syed Mansoor. Evaluation of the possible anti hyperglycemic and hypoglycemic effect of different extracts of Brassica oleracea (Unpublished PG dissertation, M.Pharm.), Rajiv Gandhi University of Health Science, Karnataka, 2003.
20. http://en.wikipedia.org/wiki/ACE-inhibitor.Access date 26/10/2009.
21. http://www.rxlist.com/perindopril-drug.htm.Access date 01/11/2009.
22. Hussam A, Philip GJ, Steven PM, James HK, Kansas City, Missouri. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of Type 2 Diabetes. J Am Coll Cardiol 2005; 46(5).
23. Zavaroni I, Mazza S, Dall’Aglio E, Gasparini P, Passeri M, Reaven GM,et al. Prevalence of hyperinsulinaemia in patients with high blood pressure. J Int Med 1992; 231:235– 40.
24. Kaplan NM. Treating hypertension in the diabetic patient. Clin Diabet 1987; 5:25–34.
25. Tenenbaum A, Fisman EZ. Impaired glucose metabolism in patients with heart failure: Pathophysiology and possible treatment strategies. Am J Cardiovasc Drugs 2004; 4:269- 80.
26. Uehara M, Kishikawa H, Isami S. Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: bradykinin may improve insulin resistance in dogs and humans. Diabetologia 1994; 37:300 –70.
27. Yang HY, Erdos EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochem Biophys Acta 1970; 214:374–76.
28. Tomiyama H, Kushiro T, Abeta H, et al. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension 1994; 23:450 –55.
29. Balon TW, Nadler JL. Evidence that nitric oxide increases glucose transport in skeletal muscle. J Appl Physiol 1997; 82:359–63.
30. Ighton B, Budohoski L, Lozeman FJ, Challiss RA, Newsholme EA.The effect of prostaglandins E1, E2 and F2α and indomethacin on the sensitivity of glycolysis and glycogen synthesis to insulin in stripped soleus muscles of the rat. Biochem J 1985; 227:337– 40.
31. Fryer LG, Hajduch E, Rencurel F. Activation of glucose transport by cAMP activated protein kinase via stimulation of nitric oxide synthase. Diabetes 2000; 49:1978–85.
32. Henriksen EJ, Jacob S, Kinnick TR, Youngblood EB, Schmit MB, Dietze GJ,et al ACE inhibition and glucose transport in insulin-resistant muscle: Roles of bradykinin and nitric oxide. Am J Physiol 1999; 277: 332–36.
33. Morel Y, Gadient A, Keller U, Vadas L, Golay A. Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol. J Cardiovasc Pharmacol 1995; 26:306 –11.
34. Ollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321:868 –73.
35. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40:609 –11.
36. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998; 41:127–33.
37. O’Keefe JH, Wetzel M, Moe RR, Bronsnahan K, Lavie CJ. Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? J Am Coll Cardiol 2001; 37:1– 8.
38. Samy I, McFarlane MD, Ashok Kumar MD and James R Sowers MD. Mechanisms by which angiotensin- converting enzyme inhibitors prevent Diabetes and Cardiovascular disease. Am J Cardiol 2003; 91(suppl):30H–37H.
39. Gavras H, Brunner HR. Role of angiotensin and its inhibition in hypertension, ischemic heart disease and heart failure. Hypertension 2001; 37:342–45.
40. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37:1053–59.
41. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37:1047–52.
42. Naftilan AJ, Zuo WM, Inglefinger J, Ryan TJ Jr, Pratt RE, Dzau VJ,et al. Localization and differential regulation of angiotensinogen mRNA expression in the vessel wall. J Clin Invest 1991; 87:1300–11.
43. Paul M, Wagner J, Dzau VJ. Gene expression of the renin-angiotensin system in human tissues: quantitative analysis by the polymerase chain reaction. J Clin Invest 1993; 91:2058–64.
44. Van Kats JP, Danser AH, van Meegen JR, Sassen LM, Verdouw PD, Schalekamp MA. Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabelled angiotensin infusions. Circulation 1998; 98:73– 81.
45. Jain S, Tang X, Narayanan CS, Agarwal Y, Peterson SM, Brown CD,et al. Angiotensinogen gene polymorphism at -217 affects basal promoter activity and is associated with hypertension in African-Americans. J Biol Chem 2002; 277:36889–96.
46. Caulfield M, Lavender P, Newell-Price J, Farrall M, Lamar S, Daniel H,et al. Linkage of the angiotensinogen gene locus to human essential hypertension in African Caribbeans. J Clin Invest 1995; 96:687–92.
47. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86:713–18.
48. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37:1053–59.
49. Ress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis risk in communities study. N Engl J Med 2000; 342:905–12.
50. Owers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med 2000; 342:969–70.
51. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A,et al. Effect of angiotensinconverting- enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril prevention project (CAPPP) randomised trial. Lancet 1999; 353:611–16.
52. Thamer M, Ray NF, Taylor T. Association between antihypertensive drug use and hypoglycemia: a case-control study of diabetic users of insulin or sulfonylureas. Clin Ther 1999; 21:1387–00.
53. Velasquez MT, Bhathena SJ, Striffler JS, Thibault N, Scalbert E. Role of angiotensin-converting enzyme inhibition in glucose metabolism and renal injury in diabetes. Metabolism 1998; 47:7–11.
54. Fogari R, Zoppi A, Lazzari P, Preti P, Mugellini A, Corradi L,et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 1998; 32:616–20.
55. McMurray J, Fraser DM. Captopril, enalapril and blood glucose. Lancet 1986; 1: 1035.
56. Passa P, Marre M, Leblanc H. Enalapril, captopril and blood glucose. Lancet 1986; 1447.
57. www.rxlist.com/amaryl-drug.htm .Access date 05/11/2009.
58. Trinder P. Ann. Clin . Biochem. 1969; 6 (24).
59. Penncock CA. Clin. Chem. Acta. 1973; 48 (193).
60. Sharp. Clin Chem Acta. 1975; 40 (115).
61. Pileggi VJ and Szuskieweiz CP. Clinical chemistry, principles and techniques. 1997; (1288).
62. Teitz NW. Fundamentals of Clinical Chemistry (243). W B Saunders and Co.
63. Young D S. Clin Chem 1972; 18(10).
64. Satyanarayana S, Prasad K, Nitin M. Pharmacodynamic drug interaction of selegiline and tolbutamide in rats. Ind Drugs 2003; 40(6): 366-8.
65. Lewis C, Barbiers AR. Streptozotocin, a new antibiotic in vitro and in vivo evaluation, Antibiot Ann 1960; 22: 247-54.
66. White FR. Sterptozotocin.Cancer Chemother Rep 1963; 29:91-98.
67. Rakieten N, Rakieten ML, Nadkarni MV. Studies on the diabetogenic action of streptozotocin. Cancer Chemother Rep 1963; 29:91-98.
68. Carter SK, Broder L, Friedman M. Streptozotocin and metastatic insulinoma. Ann Intern Med 1971; 74:445-446.
69. Weiss RB. Streptozotocin: a review of its pharmacology, efficacy and toxicity. Cancer Treat Rep 1982; 66:427-38.
70. Wilson GL, Hartig PC, Patton NJ, LeDoux SP. Mechanisms of nitrosourea induced β-cell damage. Activation of poly (ADP-ribose) synthetase and cellular distribution. Diabetes 1988; 37:213-16.
71. Sato Y, Hotta N, Sakamoto N, Matsuoka S, Ohishi N, Yagi K. Lipid peroxide level in plasma of diabetic patients. Biochem Med 1979; 21:104-07.
72. Nukatsuka M, Sakurai H, Yoshimura Y, Nishida M, Kawada J. Enhancement by streptozotocin of O2•- radical generation by the xanthine oxidase system of pancreatic β-cells. FEBS Lett 1988; 239:295-98.
73. Takasu N, Komiya I, Asawa T, Nagasawa Y, Yamada T. Streptozocin and alloxan-induced H2O2 generation and DNA fragmentation in pancreatic islets: H2O2 as mediator for DNA fragmentation. Diabetes 1991; 40:1141-45.
74. Kwon NS, Lee SH, Choi CS, nitric oxide generation from streptozotocin. Fed Am S Exp Biol 1994.
75. Lukic ML, Stosic-Grujicic S, Ostojic N, Chan WL, Liew FY. Inhibition of nitric oxide generation affects the induction of diabetes by streptozocin in mice. Biochem Biophys Res Commun 1981; 178:913-20.
76. Bedoya FJ, Solano F, Lucas M. N-monomethyl-arginine and nicotinamide prevent streptozotocin-induced double strand DNAs break formation in pancreatic rat islets. Experientia 1996; 52:344-47.
77. Kumar A, llavarsan R.antidiabetic activity of syzygium cumini and its isolated compound against streptozotocin-induced diabetic rats. J of medicial plants Research 2008 ;2(9),246-49.